Stay updated with breaking news from ரம்யா டுவிவேடி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a recent bioRxiv preprint, the large team of researchers evaluated a SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model. This study addresses the need for a next-generation, efficacious vaccine with an increased pan-SARS breadth of coverage. ....
Researchers explore an inhalable SARS-CoV-2 nanobody therapy The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the world’s third major coronavirus outbreak. To date, the SARS-CoV-2 has infected over 135 million lives and caused over 2.9 million deaths. Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. In a recent paper, published in the journal MedComm, they reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD. ....
The interaction between blood clotting and SARS-CoV-2 infection The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China, in late December 2019. The virus triggers multiple clinical complications in humans and can lead to COVID-19 (coronavirus disease 2019). To date, SARS-CoV-2 has infected over 132 million individuals and caused over 2.88 million deaths worldwide. Image Credit: SciePro / Shutterstock COVID-19 is a heterogeneous disease, primarily characterized by fever, cough and acute respiratory distress syndrome (ARDS), and in-hospital mortality. Severe COVID-19 is associated with comorbidities such as cardiovascular disease, hypertension, and diabetes mellitus and coagulopathy. Coagulopathy - a condition in which the blood s ability to clot is impaired, is recognized as a significant aspect of morbidity in COVID-19 patients. In a recent study, Prof Lewis Cantley and a team of researchers explored the role of coagula ....
Can limiting the priming dose of a SARS CoV-2 vaccine improve immunity? news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Can asymptomatic COVID-19 confer long-term immunity? The coronavirus disease 2019 (COVID-19) is a heterogeneous disease caused by the novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A significant number of SARS-CoV-2 infections, however, occur without any evident symptoms. In such asymptomatic cases, the role of humoral immunity is unclear. Are antibodies elicited from asymptomatic cases? And, if so, how long do they last? To address some of these pressing questions, a team of researchers recently compared antibody responses in 405 asymptomatic individuals with 459 symptomatic COVID-19 patients. They found that IgM responses rapidly declined in both groups. However, they found striking differences concerning the strength and persistence of SARS-CoV-2-specific IgG responses. The team has released their results on the ....